Chemotherapy of Acute Myelocytic Leukemia of AdultsI: A Study of Influences of Chemotherapy on Survival Time
Chemotherapy of Acute Myelocytic Leukemia of AdultsI: A Study of Influences of Chemotherapy on Survival Time
复制标题
成人急性粒细胞白血病的化疗I：化疗对生存时间影响的研究
DOI：
10.1093/oxfordjournals.jjco.a039860
复制
发表时间：
1975
期刊：
影响因子：
--
通讯作者：
T. Sakano
中科院分区：
文献类型：
--
作者：
T. Sakano
1948年Farberet等报道一例儿童急性白血病用嘌呤拮抗剂氨基喋呤完全缓解后，急性白血病的化疗没有取得显著进展，成人急性粒细胞白血病的生存时间显示，在单纯支持治疗的年代，生存时间为2.0-2.2个月，但事实上，由于复杂的抗白血病药物的显著增加，存活时间已经延长。我对缓解率、缓解时间和生存时间进行了研究，并着重探讨了它们与化疗各因素的关系。
No remarkable progress had been made in the chemotherapy of acute leukemia before 1948 when Farberet al. reported a case of complete remission from acute leukemia of children with aminopterine, a purine antagonist.The survival time for cases of adult acute myelocytic leukemia reveals that the survival time was 2.0–2.2 months in the years when supportive therapy alone was provided, but it is a fact that the survival time has been extended due to the growing marked availability of sophisticated antileukemic agents. I conducted a study on the remission rate, duration of remission and survival time with particular reference to their relations with various factors of chemotherapy.